Pharmaceuticals

JINLING PHARM.

JINLING PHARM. released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 768.67 M, actual EPS CNY 0.045

Jinling Pharm. to Release FY2026 Q1 Earnings on April 28 After-Market BJT

JINLING PHARM. released FY2025 Q4 earnings on March 30 After-Market (BJT), actual revenue CNY 817.18 M, actual EPS CNY -0.0233

JINLING PHARM. released FY2025 earnings on March 30 After-Market (BJT), actual revenue CNY 3.197 B, actual EPS CNY 0.0867

JINLING PHARM. FY2025 Annual Earnings Release Scheduled for March 31, 2026 After-Market BJT

JINLING PHARM. released FY2025 9 Months earnings on October 27 During-Market BJT, actual revenue CNY 2.38 B, actual EPS CNY 0.11

JINLING PHARM. released FY2025 Q3 earnings on October 27 During-Market (BJT), actual revenue CNY 779.07 M, actual EPS CNY 0.0323

JINLING PHARM. FY2025 Q3 Earnings Release on October 28, 2025 During-Market (BJT)

JINLING PHARM. released FY2025 Semi-Annual earnings on August 27 Pre-Market (BJT), actual revenue CNY 1.601 B, actual EPS CNY 0.0777

JINLING PHARM. released FY2025 Q2 earnings on August 27 Pre-Market BJT, actual revenue CNY 791.06 M, actual EPS CNY 0.0406

JINLING PHARM. to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

Jinling Pharmaceutical Submits New Trademark Registration Application

Jinling Pharmaceutical Subsidiary Receives Eleragolix Filing Acceptance Notice

Jinling Pharmaceutical Subsidiary Approved to Produce Ferrous Succinate API

Jinling Pharmaceutical Co., Ltd. Subsidiary Receives Acceptance Notice for Calcium Sufhyram Powder Suspension

Jinling Pharmaceutical Reports Revenue and Net Profit Decrease in 1Q 2025

JINLING PHARM. released FY2025 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 810.01 M, actual EPS CNY 0.037

Jinling Pharm. FY2025 Q1 Earnings Release on April 28 After-Market BJT

JINLING PHARM. released FY2024 Annual Earnings on March 28 After-Market (BJT), actual revenue CNY 3.281 B, actual EPS CNY 0.0682

Jinling Pharm. released FY2024 Q4 earnings on March 28 After-Market (BJT), actual revenue CNY 1.061 B, actual EPS CNY -0.0505

688166

000919

600267

002361

603698

As of the midday close on April 15, the Shanghai Composite Index rose 0.37%, the Shenzhen Component Index fell 0.25%, and the GEM Index dropped 0.23%. Innovative drug concept stocks such as BrightGene, HISUN, and JINLING PHARM. performed strongly, hitting the limit up. Commercial aerospace concepts also continued to rise, with CETEC, Hualing Cables, and SHENJIAN GUFEN all hitting the limit up. In contrast, oil and gas stocks declined, with Meineng Energy touching the limit down; the lithium battery sector adjusted, with Haikexinyuan falling more than 10%. Overall, individual stocks showed more declines than gains, with total trading volume reaching 1.59 trillion yuan

Wallstreetcn

BrightGene

HISUN

SHENJIAN GUFEN

CETEC

ChiNext

SSE Index

HUNAN VALIN WIRE&CABLE

WG Tech

Meineng Energy

Hi-Tech Spring

Shenzhen Index

April 15 Midday Market Review: GEM Index Opens High and Falls, Closing Down 0.23%; Innovative Drug Concepts Rally Collectively

02513

002793

002589

In the morning session, the CPO concept strengthened again, with DSBJ hitting the daily limit, EverProX rising over 5% to continue setting new record highs, and LINKTEL TECHNOLOGIES, Huamao Technology, TACLINK, and CIG following the gains. Innovative drug stocks were active against the trend in the morning, with YIBAI PHARMACEUTICAL achieving three daily limits in six days, Menovo hitting the daily limit, and Jincheng Pharm, JINLING PHARM., Luoxin Pharmaceutical, and Realcan following the upward trend

KNOWLEDGE ATLAS

Luoxin Pharmaceutical

Realcan

DSBJ

EverProX

TACLINK

Jincheng Pharm

Menovo

LINKTEL TECHNOLOGIES

YIBAI PHARMACEUTICAL

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

Tianhong CSI Computer Theme ETF

GTJA Allianz SSE STAR Chip Design Thematic ETF

ChinaAMC SSE STAR Semiconductor Material & Equipment Thematic ETF

Guotai CSI Computer Theme ETF

China Southern CSI Semiconductor Industry Custom ETF

Guotai CES Semiconductor Chip Industry ETF

ChinaAMC Guozheng Semiconductor Chip ETF

A-share Three Major Indices Fell Collectively, Computing Hardware Active Against the Trend, Hang Seng Tech Index Down Over 1%, AI Large Model Stocks Rebound, KNOWLEDGE ATLAS Rises 7%

JINLING PHARM. announced that its revenue for the third quarter was 779 million yuan, a year-on-year decrease of 4.53%; net profit was 20.1248 million yuan, a year-on-year decrease of 1.84%. Revenue for the first three quarters was 2.38 billion yuan, a year-on-year decrease of 5.95%; net profit was 68.4583 million yuan, a year-on-year decrease of 10.81%

Zhitong

JINLING PHARM.: Net profit in the third quarter was 20.1248 million yuan, a year-on-year decrease of 1.84%

JINLING PHARM. announced that its subsidiary JINLING Pharmaceutical Factory has received approval from the National Medical Products Administration to conduct Phase III clinical research on Elagolix tablets. Elagolix tablets are a GnRH antagonist primarily used to treat moderate to severe pain associated with endometriosis. This drug has been included in the national "Second Batch of Encouraged Generic Drug List."

JINLING PHARM.: Olaratumab tablets approved to conduct Phase III clinical research

JINLING PHARM.'s subsidiary Chizhou Dongsheng Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration to list potassium sulfate, meeting domestic drug registration requirements, and can be produced and sold in the domestic market. This will enrich the company's active pharmaceutical ingredient product line, but will have little impact on the company's performance in the short term

JINLING PHARM.: The holding subsidiary has received approval for the listing of potassium sulfate

JINLING PHARM.'s Fuzhou Meifeng Pharmaceutical Factory has received approval from the Fujian Provincial Drug Administration for the re-registration of hydrolyzed protein injection. The specification of this drug is 500ml:25g, mainly used for severe amino acid deficiency and hypoproteinemia. Although the approval helps restore production and sales, the recent performance impact is minimal, and market and policy factors bring uncertainty, reminding investors to pay attention to risks

JINLING PHARM.: Fuzhou Meifeng Pharmaceutical Factory's hydrolyzed protein injection has received re-registration approval

JINLING PHARM.'s subsidiary Nanjing JINLING Pharmaceutical Factory recently received the acceptance notice from the National Medical Products Administration for the application of domestic production drug registration clinical trials for Elagolix tablets. Elagolix is a GnRH antagonist that was approved by the FDA in 2018, specifically for the treatment of moderate to severe pain associated with endometriosis. If the clinical trials go smoothly, it will enhance the company's product line and competitiveness

JINLING PHARM. branch received the acceptance notice for Olaratumab tablets

JINLING PHARM.'s holding subsidiary Chizhou Dongsheng Pharmaceutical recently received approval from the National Medical Products Administration to list the chemical raw material drug ferrous succinate. This approval will enrich the company's raw material drug product line, promote integrated development of the industrial chain, and help ensure stable supply of the main product ferrous succinate tablets, enhance market competitiveness, and support the company's continuous and stable development

JINLING PHARM.'s subsidiary has received approval for the marketing of ferrous succinate chemical raw materials

According to the Zhitong Finance APP, JINLING PHARM. announced that its subsidiary, Nanjing JINLING Pharmaceutical Factory, recently received the acceptance notice for the carbonic acid sevelamer dry suspension issued by the National Medical Products Administration. Carbonic acid sevelamer is an insoluble polymer drug primarily used for the treatment of hyperphosphatemia in adult patients with chronic kidney disease (CKD) who are undergoing dialysis treatment

JINLING PHARM.: The registration application for carbonic acid sevelamer dry suspension has been accepted

JINLING PHARM.(000919.SZ)